证券研究报告·北交所公司点评报告·电池 远航精密（833914） 2025 中报点评：镍带、箔持续稳健增长，精 密结构件放量高增，固态有望贡献新增量 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 809.67 | 852.18 | 1,131.69 | 1,435.84 | 1,899.73 | | 同比 | (10.59) | 5.25 | 32.80 | 26.88 | 32.31 | | 归母净利润（百万元） | 31.61 | 67.44 | 80.68 | 104.60 | 132.89 | | 同比 | (40.87) | 113.37 | 19.62 | 29.65 | 27.05 | | EPS-最新摊薄（元/股） | 0.32 | 0.67 | 0.81 | 1.05 | 1.33 | | P/E（现价&最新摊薄） | 116.11 | 54.42 | 45.49 | 35.09 | 27.6 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q2 cost reduction efforts have shown significant results, and there is considerable price elasticity expected in the second half of the year [8] - The company achieved a revenue of 3.69 billion yuan in H1 2025, a year-on-year decrease of 17.8%, with a net profit attributable to shareholders of 400 million yuan, down 47.8% year-on-year [8] - The lithium carbonate sales volume in H1 2025 was 12,000 tons, with expectations of reaching 25,000 to 26,000 tons for the entire year [8] - The company is expected to maintain a low cost level in the second half of the year, with lithium prices projected to fluctuate around 80,000 yuan per ton, potentially contributing 300 million yuan in profit [8] - The company’s investment income significantly increased, with a 143% year-on-year growth in H1 2025 [8] - The profit forecast for the company has been adjusted, with expected net profits of 900 million yuan, 1.11 billion yuan, and 1.67 billion yuan for 2025, 2026, and 2027 respectively [8] Financial Summary - The total revenue forecast for 2023 is 12.19 billion yuan, with a year-on-year decrease of 21.76% [1] - The net profit attributable to shareholders for 2023 is projected at 3.41 billion yuan, reflecting a year-on-year decrease of 46.09% [1] - The earnings per share (EPS) for 2023 is estimated at 6.32 yuan, with a P/E ratio of 5.54 [1] - The company’s total assets are projected to reach 15.25 billion yuan by 2025, with a debt ratio of 9.84% [6][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's industrial segment is expected to achieve a 14% growth in net profit attributable to the parent company by 2025, with a rapid advancement in the innovative drug pipeline [1] - The company reported a total revenue of 40,624 million yuan in 2023, with a year-on-year growth of 7.71%, and a projected revenue of 44,552 million yuan in 2025, reflecting a growth of 6.32% [1] - The net profit attributable to the parent company is forecasted to reach 3,932 million yuan in 2025, representing an 11.95% increase compared to the previous year [1] Financial Forecasts - Total revenue projections for 2024, 2025, 2026, and 2027 are 41,906 million yuan, 44,552 million yuan, 47,706 million yuan, and 50,406 million yuan respectively [9] - The net profit attributable to the parent company is expected to be 3,512 million yuan in 2024, 3,932 million yuan in 2025, 4,421 million yuan in 2026, and 4,950 million yuan in 2027 [9] - The earnings per share (EPS) is projected to be 2.00 yuan in 2024, 2.24 yuan in 2025, 2.52 yuan in 2026, and 2.82 yuan in 2027 [9] Business Segments - The industrial segment's revenue for the first half of 2025 was 73.17 billion yuan, with a year-on-year growth of 9.24%, and the net profit was 15.80 billion yuan, increasing by 14.09% [8] - The innovative product business generated revenue of 10.84 billion yuan in the first half of 2025, marking a significant increase of 59% [8] - The medical beauty segment reported revenue of 11.12 billion yuan in the first half of 2025, although it experienced a decline of 17.5% year-on-year [8] R&D and Product Development - The company is advancing over 80 innovative drug pipelines, with significant progress in various therapeutic areas including endocrinology and ADC [8] - The medical beauty products are accelerating registration, with several products expected to launch in both domestic and international markets [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a recovery in the European electronic vaporization market, and the HNB (Heat-not-Burn) segment is expected to release profit elasticity [8] - The company's revenue for the first half of 2025 reached 6.013 billion yuan, a year-on-year increase of 18.3%, aligning with forecast values and exceeding initial high single-digit expectations [8] - The HNB market is in a rapid growth phase, with the company collaborating with British American Tobacco on new products, indicating potential for future profit contributions [8] Financial Summary - Total revenue projections for the company are as follows: - 2023A: 11.177 billion yuan - 2024A: 11.799 billion yuan - 2025E: 13.722 billion yuan - 2026E: 16.166 billion yuan - 2027E: 18.395 billion yuan - Year-on-year growth rates are projected at (8.06)%, 5.56%, 16.30%, 17.81%, and 13.79% respectively [1] - Net profit attributable to the parent company is forecasted as: - 2023A: 1.645 billion yuan - 2024A: 1.303 billion yuan - 2025E: 1.329 billion yuan - 2026E: 2.217 billion yuan - 2027E: 2.891 billion yuan - Year-on-year growth rates are projected at (34.47)%, (20.78)%, 1.96%, 66.84%, and 30.40% respectively [1] - The latest diluted EPS (Earnings Per Share) is projected as follows: - 2023A: 0.27 yuan - 2024A: 0.21 yuan - 2025E: 0.21 yuan - 2026E: 0.36 yuan - 2027E: 0.47 yuan [1] - The P/E (Price-to-Earnings) ratios at current price and latest diluted EPS are: - 2023A: 80.56 - 2024A: 101.69 - 2025E: 99.73 - 2026E: 59.78 - 2027E: 45.84 [1]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance in the first half of 2025 met market expectations, with revenue of 11.33 billion and a year-on-year increase of 8.9%, while net profit attributable to shareholders reached 600 million, up 30.1% year-on-year [9] - The growth foundation is built on UHV (Ultra High Voltage) and power transmission and transformation, with transformer profitability continuously improving [9] - The company is actively expanding its overseas market, achieving a 64% year-on-year increase in overseas revenue to 2.171 billion [9] - High R&D investment is maintained, with inventory growth attributed to a backlog of finished products [9] Summary by Sections Financial Performance - Total revenue for 2023 is projected at 21.204 billion, with a year-on-year growth of 13.02% [1] - Net profit attributable to shareholders for 2023 is estimated at 897.17 million, reflecting a 44.92% increase year-on-year [1] - The latest diluted EPS for 2023 is expected to be 0.18 yuan per share [1] Revenue and Profit Forecast - Revenue is forecasted to grow to 24.476 billion in 2025, with a year-on-year increase of 9.85% [1] - Net profit attributable to shareholders is projected to reach 1.497 billion in 2025, representing a 42.04% increase year-on-year [1] - The P/E ratio for 2025 is estimated at 22.97 [1] Market Position and Growth Drivers - The company has a solid order backlog in the UHV sector, with multiple projects expected to start bidding in the second half of the year [9] - The company is also focusing on the distribution network and international expansion as key growth drivers [9] - The gross margin for the first half of 2025 was reported at 21.6%, an increase of 2.7 percentage points year-on-year [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in the first half of 2025 is in line with market expectations, with significant improvements in quality and efficiency [8] - The company has achieved robust growth in its power distribution business, particularly in overseas markets, which is becoming a key growth driver [8] - The rehabilitation hospital business faces some pressure, but long-term demand remains strong [8] - The company has effectively controlled costs, leading to a notable reduction in expenses [8] - The long-term outlook for the overseas power distribution market is positive, with strong competitive advantages [8] Financial Summary - Total revenue for 2023 is projected at 11,463 million, with a year-on-year growth of 25.99% [1] - Net profit attributable to shareholders for 2023 is expected to be 1,904 million, reflecting a year-on-year increase of 100.79% [1] - The earnings per share (EPS) for 2023 is estimated at 1.35 yuan, with a price-to-earnings (P/E) ratio of 18.20 [1] - The company anticipates total revenue of 18,034 million in 2025, with a year-on-year growth of 23.51% [1] - The net profit attributable to shareholders for 2025 is projected at 2,511 million, with a year-on-year growth of 11.14% [1] - The EPS for 2025 is expected to be 1.79 yuan, with a P/E ratio of 13.80 [1]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a revenue growth of 25% year-on-year in Q2 2025, indicating significant results from its reform efforts [8] - The company is recognized as a well-known domestic daily chemical brand with a comprehensive brand matrix and extensive channel coverage [8] - The report highlights a turning point in operations as the company actively adjusts its brand, products, and marketing strategies [8] Financial Performance Summary - For H1 2025, the company reported a total revenue of 3.48 billion yuan, a year-on-year increase of 4.7%, and a net profit attributable to shareholders of 270 million yuan, up 11.7% year-on-year [8] - In Q2 2025, the company achieved a revenue of 1.77 billion yuan, a year-on-year increase of 25.4%, and a net profit of 50 million yuan, marking a turnaround [8] - The gross margin for H1 2025 was 63.37%, an increase of 2.24 percentage points year-on-year, while the gross margin for Q2 2025 was 63.34%, up 5.09 percentage points year-on-year [8] - The report forecasts net profits for 2025-2027 to be 320 million, 410 million, and 540 million yuan respectively, with year-on-year growth rates of 139%, 27%, and 32% [8] Segment Performance Summary - The personal care and beauty segments showed high growth, with Q2 2025 revenues of 800 million yuan and 420 million yuan, representing year-on-year increases of 42.4% and 55.7% respectively [8] - The online sales channel in Q2 2025 saw a revenue increase of 34.6%, with online and offline sales accounting for 44.2% and 55.8% respectively [8] Brand and Product Development - The company has launched upgraded products and collaborated with popular IPs, leading to increased market share in key categories [8] - The brand "Six God" ranked first in various online sales categories, contributing to a 3 percentage point increase in market share for its mosquito repellent products [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's overall performance in the first half of 2025 met market expectations, with significant improvement in profitability [8] - The direct current transmission business continues to grow rapidly, while high voltage projects are progressing steadily [8] - The company is experiencing pressure on revenue from distribution and metering products, but cost control measures are enhancing profitability [8] - International market expansion is showing promising results, with substantial growth in overseas revenue [8] - The company has increased its investment in sales system construction, leading to a significant rise in contract liabilities and cash flow exceeding profits [8] - Profit forecasts have been adjusted downward due to delays in high voltage project approvals and price reductions in distribution products, but the company still shows strong growth potential [8] Financial Summary - Total revenue for 2023 is projected at 17,061 million RMB, with a year-on-year growth of 13.51% [1] - Net profit attributable to shareholders is expected to reach 1,005 million RMB in 2023, reflecting a year-on-year increase of 28.03% [1] - The latest diluted EPS is forecasted to be 0.99 RMB per share for 2023, with a P/E ratio of 23.59 [1] - For 2025, total revenue is estimated at 17,960 million RMB, with a year-on-year growth of 5.09% [1] - The net profit attributable to shareholders for 2025 is projected at 1,426 million RMB, indicating a year-on-year increase of 27.67% [1] - The P/E ratio for 2025 is expected to be 16.63 [1]

证券研究报告·海外公司点评·公用事业Ⅱ(HS) 昆仑能源（00135.HK） 2025 年中报点评：售气价差回落&补贴确认 减少导致业绩承压，DPS 提升 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 177,726 | 187,046 | 194,158 | 206,079 | 217,252 | | 同比(%) | 3.16 | 5.24 | 3.80 | 6.14 | 5.42 | | 归母净利润（百万元） | 5,682 | 5,960 | 6,061 | 6,341 | 6,635 | | 同比(%) | 8.68 | 4.89 | 1.70 | 4.61 | 4.63 | | EPS-最新摊薄（元/股） | 0.66 | 0.69 | 0.70 | 0.73 | 0.77 | | P/E（现价&最新摊薄） | 10.29 | 9.81 | 9.65 | 9.22 | 8.81 | [Table_Ta ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company shows a clear upward trend with accelerated improvement in Q2 2025, indicating a positive outlook for future performance [8] - The company achieved a total revenue of 835 million yuan in H1 2025, representing a year-on-year growth of 9.31%, and a net profit attributable to shareholders of 132 million yuan, up 18.08% year-on-year [8] - The main brand's net store openings and same-store sales turned positive in Q2, reflecting further improvement in fundamentals [8] - Cost reductions have positively impacted profitability, with a gross margin of 28.2% in Q2 2025, an increase of 1.8 percentage points year-on-year [8] - The company is expected to continue expanding its store count and market share through acquisitions and operational efficiencies [8] Financial Performance Summary - Total revenue projections for the company are as follows: 1,884 million yuan in 2025, 2,123 million yuan in 2026, and 2,293 million yuan in 2027, with year-on-year growth rates of 12.71%, 12.69%, and 8.00% respectively [1] - Net profit attributable to shareholders is forecasted to be 289 million yuan in 2025, 327 million yuan in 2026, and 361 million yuan in 2027, with growth rates of 4.59%, 12.97%, and 10.53% respectively [1] - The latest diluted EPS is projected to be 1.21 yuan in 2025, 1.36 yuan in 2026, and 1.51 yuan in 2027 [1] - The company’s P/E ratios are expected to be 18.39 in 2025, 16.27 in 2026, and 14.72 in 2027 [1]